Ipamorelin

Research studies describe Ipamorelin as a selective agonist at the growth hormone secretagogue receptor, the same receptor that binds the endogenous hormone ghrelin. In animal models, researchers have reported that Ipamorelin stimulates pulsatile growth hormone release from the pituitary. Published research also notes that the non-natural amino acids in Ipamorelin were chosen to improve receptor selectivity and resistance to enzymatic breakdown.

The primary research area for Ipamorelin is growth hormone secretion. In rodent and swine studies, researchers reported that Ipamorelin produced growth hormone release without the meaningful rise in cortisol or ACTH that was observed with earlier secretagogues such as GHRP-6. That selectivity is the main reason Ipamorelin has been used as a reference compound in secretagogue pharmacology.

Beyond growth hormone release, Ipamorelin has been studied in animal models of gastrointestinal motility, where researchers reported examining its effect on gastric emptying after surgery. Rodent studies have also looked at bone density and body composition endpoints. In research studies, Ipamorelin has been observed to have little effect on appetite compared with ghrelin itself, which has made it useful for separating those two receptor-driven effects.

The evidence for Ipamorelin comes from in vitro receptor binding work, animal models in rats and pigs, and a small number of early clinical trials. A phase 2 program that examined Ipamorelin in postoperative ileus was discontinued, and the compound was never approved as a drug. Ipamorelin remains an investigational research peptide with a preclinical evidence base.

Ipamorelin and Sermorelin act on different receptors. Ipamorelin is a ghrelin receptor agonist that researchers have reported triggers growth hormone pulses directly from pituitary cells. Sermorelin is a 29-amino acid fragment of growth hormone releasing hormone that acts on the GHRH receptor. Research studies have paired the two classes because they work through separate signaling routes on the same pituitary cells. Biotech Compounds sells both as separate research products.

Ipamorelin is supplied as a lyophilized powder and is soluble in sterile water or Bacteriostatic Water. Researchers add the diluent slowly against the inside of the vial and swirl gently until the solution is clear. The vial should not be shaken. Bacteriostatic Water is the usual choice when the reconstituted Ipamorelin solution will be drawn from more than once in the laboratory.

Lyophilized Ipamorelin should be stored at minus 20 C, protected from light and moisture. After reconstitution, the solution should be refrigerated at 2 to 8 C and protected from light. Repeated freeze thaw cycles should be avoided, so aliquoting is recommended if long-term frozen storage is needed. Researchers have reported that Ipamorelin has a short plasma half-life in animal models, measured in hours, although the lyophilized form is stable for extended periods when kept cold.

Yes. Ipamorelin from Biotech Compounds is listed at 99 percent plus purity. Each lot is analyzed by an independent third-party laboratory for identity and purity, and the Certificate of Analysis is available on the product page. Researchers can review the COA for the specific Ipamorelin lot before it is used in an experiment.

Ipamorelin has an approximate molecular weight of 711 Da and a molecular formula of C38H49N9O5. As a pentapeptide with an amidated C-terminus, Ipamorelin is small compared with most growth hormone secretagogues. The five residues include two D-amino acids and one aminoisobutyric acid, which research studies have described as contributing to the metabolic stability of Ipamorelin in solution.

No. Ipamorelin is sold by Biotech Compounds strictly as a research material for laboratory research by qualified researchers and research organizations. Purchasers must be 21 years of age or older. Ipamorelin is not a drug or a dietary supplement, has not been approved by the FDA, and is not for human or animal consumption.